Pancreatic Cancer News & Features
Pancreatic cancer may potentially be safely and effectively treated with immunochemotherapy, according to recent research from a preclinical study.
Olaparib, an experimental oral cancer drug, has shown an overall tumor response rate of 26% in advanced cancers associated with BRCA1 and BRCA2 mutations, according to recent research.
Increased expression of a microRNA (miRNA) panel seems highly accurate for diagnosis of pancreatic ductal adenocarcinoma (PDAC), according to a study published online.
New research that provides a better understanding of pancreatic cancer may help identify those people at increased risk.
Patients with a family history of pancreatic cancer may be at an increased risk for developing the disease.
- Key discovery in understanding successes and failures of immunotherapy
- Researchers identify biological indicator of response to new ovarian cancer drug
- Managing obesity should be part of cancer care
- Galeterone active in one form of castration-resistant prostate cancer
- Reducing side effects of everolimus administration
- Navigation and survivorship: Rationalizing your program costs
- Monitoring psychosocial function in radiotherapy
- Comparison of medications for managing nausea and vomiting
- Comparison of constipation management medications
- Chemo- and immunotherapy combination is a promising treatment for pancreatic cancer
- High tumor immune cell levels may identify women with HER2+ breast cancer who may benefit from chemotherapy alone
- Hair Dyes and Cancer Risk (Fact Sheet)
- For bladder cancer, laparoscopic radical cystectomy effective at preventing recurrence
- Aspirin and/or NSAID use may improve risk of high-grade prostate cancer
- Modifying lifestyle, HPV vaccine can help prevent anal cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|